ID   FGFR2_HUMAN             Reviewed;         821 AA.
AC   P21802; P18443; Q01742; Q12922; Q14300; Q14301; Q14302; Q14303;
AC   Q14304; Q14305; Q14672; Q14718; Q14719; Q1KHY5; Q86YI4; Q96KL9;
AC   Q96KM0; Q96KM1; Q96KM2; Q9NZU2; Q9NZU3; Q9UD01; Q9UD02; Q9UIH3;
AC   Q9UIH4; Q9UIH5; Q9UIH6; Q9UIH7; Q9UIH8; Q9UM87; Q9UMC6; Q9UNS7;
AC   Q9UQH7; Q9UQH8; Q9UQH9; Q9UQI0;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   02-NOV-2010, entry version 152.
DE   RecName: Full=Fibroblast growth factor receptor 2;
DE            Short=FGFR-2;
DE            EC=2.7.10.1;
DE   AltName: Full=K-sam;
DE   AltName: Full=Keratinocyte growth factor receptor;
DE   AltName: CD_antigen=CD332;
DE   Flags: Precursor;
GN   Name=FGFR2; Synonyms=BEK, KGFR, KSAM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Neonatal brain stem;
RX   MEDLINE=90360977; PubMed=1697263;
RA   Dionne C.A., Crumley G.R., Bellot F., Kaplow J.M., Searfoss G.,
RA   Ruta M., Burgess W.H., Jaye M., Schlessinger J.;
RT   "Cloning and expression of two distinct high-affinity receptors cross-
RT   reacting with acidic and basic fibroblast growth factors.";
RL   EMBO J. 9:2685-2692(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 16).
RX   MEDLINE=91045961; PubMed=2172978; DOI=10.1073/pnas.87.20.8180;
RA   Houssaint E., Blanquet P.R., Champion-Arnaud P., Gesnel M.-C.,
RA   Torriglia A., Courtois Y., Breathnach R.;
RT   "Related fibroblast growth factor receptor genes exist in the human
RT   genome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8180-8184(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 17).
RX   MEDLINE=91274356; PubMed=1647213; DOI=10.1016/0167-4781(91)90015-E;
RA   Seno M., Sasada R., Watanabe T., Ishimaru K., Igarashi K.;
RT   "Two cDNAs encoding novel human FGF receptor.";
RL   Biochim. Biophys. Acta 1089:244-246(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Stomach cancer;
RX   MEDLINE=90332706; PubMed=2377625; DOI=10.1073/pnas.87.15.5983;
RA   Hattori Y., Odagiri H., Nakatani H., Miyagawa K., Naito K.,
RA   Sakamoto H., Katoh O., Yoshida T., Sugimura T., Terada M.;
RT   "K-sam, an amplified gene in stomach cancer, is a member of the
RT   heparin-binding growth factor receptor genes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5983-5987(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 14 AND 15).
RX   MEDLINE=92212948; PubMed=1313574; DOI=10.1073/pnas.89.7.2960;
RA   Katoh M., Hattori Y., Sasaki H., Tanaka M., Sugano K., Yazaki Y.,
RA   Sugimura T., Terada M.;
RT   "K-sam gene encodes secreted as well as transmembrane receptor
RT   tyrosine kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:2960-2964(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Placenta;
RX   MEDLINE=93016048; PubMed=1400433;
RA   Dell K.R., Williams L.T.;
RT   "A novel form of fibroblast growth factor receptor 2. Alternative
RT   splicing of the third immunoglobulin-like domain confers ligand
RT   binding specificity.";
RL   J. Biol. Chem. 267:21225-21229(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 19), AND VARIANT ARG-613.
RC   TISSUE=Mammary gland;
RX   MEDLINE=92108030; PubMed=1309608; DOI=10.1073/pnas.89.1.246;
RA   Miki T., Bottaro D.P., Fleming T.P., Smith C.L., Burgess W.H.,
RA   Chan A.M.-L., Aaronson S.A.;
RT   "Determination of ligand-binding specificity by alternative splicing:
RT   two distinct growth factor receptors encoded by a single gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:246-250(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 19).
RC   TISSUE=Cornea, and Mammary gland;
RX   MEDLINE=95170769; PubMed=7866434;
RA   Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M.,
RA   Shay J.W.;
RT   "Hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), and
RT   their receptors in human breast cells and tissues: alternative
RT   receptors.";
RL   Cell. Mol. Biol. Res. 40:337-350(1994).
RN   [9]
RP   ERRATUM.
RA   Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M.,
RA   Shay J.W.;
RL   Cell. Mol. Biol. Res. 40:707-707(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT CS SER-342.
RC   TISSUE=Blood;
RA   Steinberger D., Mueller U.;
RL   Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 7; 9; 10; 11; 12 AND 13), AND
RP   VARIANT ARG-613.
RX   MEDLINE=20090220; PubMed=10626794;
RA   Ueda T., Sasaki H., Kuwahara Y., Nezu M., Shibuya T., Sakamoto H.,
RA   Ishii H., Yanagihara K., Mafune K., Makuuchi M., Terada M.;
RT   "Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short
RT   homology-mediated recombination, generating preferential expression of
RT   specific messenger RNAs.";
RL   Cancer Res. 59:6080-6086(1999).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 5; 6; 8; 14 AND 18).
RX   MEDLINE=21845873; PubMed=11856867;
RA   Ingersoll R.G., Paznekas W.A., Tran A.K., Scott A.F., Jiang G.,
RA   Jabs E.W.;
RT   "Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and
RT   variations.";
RL   Cytogenet. Cell Genet. 94:121-126(2001).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 3).
RA   Lind D.L., Cox D.R.;
RT   "Sequence and polymorphisms in fibroblast growth factor receptor 2
RT   (FGFR2) gene in humans.";
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-6 AND THR-186.
RG   NIEHS SNPs program;
RL   Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 20).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 314-427.
RX   MEDLINE=20177482; PubMed=10712195; DOI=10.1086/302831;
RA   Glaser R.L., Jiang W., Boyadjiev S.A., Tran A.K., Zachary A.A.,
RA   Van Maldergem L., Johnson D., Walsh S., Oldridge M., Wall S.A.,
RA   Wilkie A.O.M., Jabs E.W.;
RT   "Paternal origin of FGFR2 mutations in sporadic cases of Crouzon
RT   syndrome and Pfeiffer syndrome.";
RL   Am. J. Hum. Genet. 66:768-777(2000).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-209; 212-767 AND 771-821
RP   (ISOFORMS 5; 14 AND 18).
RX   MEDLINE=99214070; PubMed=10196476; DOI=10.1016/S0378-1119(99)00047-5;
RA   Zhang Y., Gorry M.C., Post J.C., Ehrlich G.D.;
RT   "Genomic organization of the human fibroblast growth factor receptor 2
RT   (FGFR2) gene and comparative analysis of the human FGFR gene family.";
RL   Gene 230:69-79(1999).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 249-313, AND VARIANTS APRS
RP   TRP-252 AND ARG-253.
RX   MEDLINE=95397814; PubMed=7668257;
RA   Park W.-J., Theda C., Maestri N.E., Meyers G.A., Fryburg J.S.,
RA   Dufresne C., Cohen M.M. Jr., Jabs E.W.;
RT   "Analysis of phenotypic features and FGFR2 mutations in Apert
RT   syndrome.";
RL   Am. J. Hum. Genet. 57:321-328(1995).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-259.
RX   MEDLINE=96253074; PubMed=8676562;
RA   Wada C., Ishigaki M., Toyo-oka Y., Yamabe H., Ohnuki Y., Takada F.,
RA   Yamazaki Y., Ohtani H.;
RT   "Nucleotide sequences at intron 6 and exon 7 junction of fibroblast
RT   growth factor receptor 2 and rapid mutational analysis in Apert
RT   syndrome.";
RL   Rinsho Byori 44:435-438(1996).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-318.
RX   MEDLINE=96241572; PubMed=8673103; DOI=10.1038/ng0596-48;
RA   Moloney D.M., Slaney S.F., Oldridge M., Wall S.A., Sahlin P.,
RA   Stenman G., Wilkie A.O.M.;
RT   "Exclusive paternal origin of new mutations in Apert syndrome.";
RL   Nat. Genet. 13:48-53(1996).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 263-361, AND VARIANTS CS PRO-289;
RP   ARG-338; SER-342; TYR-342; GLY-344 AND CYS-354.
RX   MEDLINE=96090259; PubMed=7581378; DOI=10.1093/hmg/4.8.1387;
RA   Gorry M.C., Preston R.A., White G.J., Zhang Y., Singhal V.K.,
RA   Losken H.W., Parker M.G., Nwokoro N.A., Post J.C., Ehrlich G.D.;
RT   "Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common
RT   point mutation shared with Jackson-Weiss syndrome.";
RL   Hum. Mol. Genet. 4:1387-1390(1995).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-448 AND THR-449, AND
RP   MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 147-366 IN COMPLEX WITH FGF2.
RX   MEDLINE=20288980; PubMed=10830168; DOI=10.1016/S0092-8674(00)80851-X;
RA   Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M.;
RT   "Crystal structures of two FGF-FGFR complexes reveal the determinants
RT   of ligand-receptor specificity.";
RL   Cell 101:413-424(2000).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 148-366 IN COMPLEX WITH FGF1
RP   AND HEPARIN.
RX   MEDLINE=20518968; PubMed=11069186; DOI=10.1038/35039551;
RA   Pellegrini L., Burke D.F., von Delft F., Mulloy B., Blundell T.L.;
RT   "Crystal structure of fibroblast growth factor receptor ectodomain
RT   bound to ligand and heparin.";
RL   Nature 407:1029-1034(2000).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 147-362 IN COMPLEX WITH FGF1.
RX   MEDLINE=20087200; PubMed=10618369; DOI=10.1073/pnas.97.1.49;
RA   Stauber D.J., DiGabriele A.D., Hendrickson W.A.;
RT   "Structural interactions of fibroblast growth factor receptor with its
RT   ligands.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:49-54(2000).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 147-366 OF VARIANTS APRS
RP   TRP-252 AND ARG-253 IN COMPLEX WITH FGF2.
RX   MEDLINE=21309918; PubMed=11390973; DOI=10.1073/pnas.121183798;
RA   Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M.,
RA   Mohammadi M.;
RT   "Structural basis for fibroblast growth factor receptor 2 activation
RT   in Apert syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:7182-7187(2001).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 140-371 IN COMPLEX WITH
RP   FGF10.
RX   MEDLINE=22506311; PubMed=12591959; DOI=10.1073/pnas.0436500100;
RA   Yeh B.K., Igarashi M., Eliseenkova A.V., Plotnikov A.N., Sher I.,
RA   Ron D., Aaronson S.A., Mohammadi M.;
RT   "Structural basis by which alternative splicing confers specificity in
RT   fibroblast growth factor receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:2266-2271(2003).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 149-368 IN COMPLEX WITH
RP   FGF8.
RX   PubMed=16384934; DOI=10.1101/gad.1365406;
RA   Olsen S.K., Li J.Y.H., Bromleigh C., Eliseenkova A.V., Ibrahimi O.A.,
RA   Lao Z., Zhang F., Linhardt R.J., Joyner A.L., Mohammadi M.;
RT   "Structural basis by which alternative splicing modulates the
RT   organizer activity of FGF8 in the brain.";
RL   Genes Dev. 20:185-198(2006).
RN   [29]
RP   VARIANTS CS HIS-340; ARG-342; SER-342; TYR-342 AND CYS-354.
RX   MEDLINE=95078932; PubMed=7987400; DOI=10.1038/ng0994-98;
RA   Reardon W., Winter R.M., Rutland P., Pulleyn L.J., Jones B.M.,
RA   Malcolm S.;
RT   "Mutations in the fibroblast growth factor receptor 2 gene cause
RT   Crouzon syndrome.";
RL   Nat. Genet. 8:98-103(1994).
RN   [30]
RP   VARIANTS CS CYS-328 AND CYS-347, AND VARIANT JWS GLY-344.
RX   MEDLINE=95179174; PubMed=7874170; DOI=10.1038/ng1194-275;
RA   Jabs E.W., Li X., Scott A.F., Meyers G.A., Chen W., Eccles M., Mao J.,
RA   Charnas L.R., Jackson C.E., Jaye M.;
RT   "Jackson-Weiss and Crouzon syndromes are allelic with mutations in
RT   fibroblast growth factor receptor 2.";
RL   Nat. Genet. 8:275-279(1994).
RN   [31]
RP   VARIANTS CS.
RX   MEDLINE=95384152; PubMed=7655462; DOI=10.1093/hmg/4.6.1077;
RA   Oldridge M., Wilkie A.O.M., Slaney S.F., Poole M.D., Pulleyn L.J.,
RA   Rutland P., Hockley A.D., Wake M.J.C., Goldin J.H., Winter R.M.,
RA   Reardon W., Malcolm S.;
RT   "Mutations in the third immunoglobulin domain of the fibroblast growth
RT   factor receptor-2 gene in Crouzon syndrome.";
RL   Hum. Mol. Genet. 4:1077-1082(1995).
RN   [32]
RP   VARIANTS CS GLY-290; TRP-342 AND CYS-354, AND VARIANT JWS ARG-342.
RX   MEDLINE=96133301; PubMed=8528214; DOI=10.1093/hmg/4.7.1229;
RA   Park W.-J., Meyers G.A., Li X., Theda C., Day D., Orlow S.J.,
RA   Jones M.C., Jabs E.W.;
RT   "Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show
RT   allelic heterogeneity and phenotypic variability.";
RL   Hum. Mol. Genet. 4:1229-1233(1995).
RN   [33]
RP   VARIANT PS ALA-321.
RX   MEDLINE=95235551; PubMed=7719333; DOI=10.1038/ng0295-108;
RA   Lajeunie E., Wei M.H., Bonaventure J., Munnich A., le Merrer M.,
RA   Renier D.;
RT   "FGFR2 mutations in Pfeiffer syndrome.";
RL   Nat. Genet. 9:108-108(1995).
RN   [34]
RP   VARIANTS APRS TRP-252 AND ARG-253.
RX   MEDLINE=95235562; PubMed=7719344; DOI=10.1038/ng0295-165;
RA   Wilkie A.O.M., Slaney S.F., Oldridge M., Poole M.D., Ashworth G.J.,
RA   Hockley A.D., Hayward R.D., David D.J., Pulleyn L.J., Rutland P.,
RA   Malcolm S., Winter R.M., Reardon W.;
RT   "Apert syndrome results from localized mutations of FGFR2 and is
RT   allelic with Crouzon syndrome.";
RL   Nat. Genet. 9:165-172(1995).
RN   [35]
RP   VARIANTS PS PRO-341; ARG-342 AND TYR-342.
RX   MEDLINE=95235563; PubMed=7719345; DOI=10.1038/ng0295-173;
RA   Rutland P., Pulleyn L.J., Reardon W., Baraister M., Hayward R.,
RA   Jones B.M., Malcolm S., Winter R.M., Oldridge M., Slaney S.F.,
RA   Poole M.D., Wilkie A.O.M.;
RT   "Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon
RT   syndrome phenotypes.";
RL   Nat. Genet. 9:173-176(1995).
RN   [36]
RP   VARIANTS CS GLY-268 INS; PHE-342 AND TYR-342, VARIANTS PS PHE-278;
RP   ARG-342; SER-342; PRO-344 AND PHE-359, AND VARIANT JWS PRO-289.
RX   MEDLINE=96203627; PubMed=8644708;
RA   Meyers G.A., Day D., Goldberg R., Daentl D.L., Przylepa K.A.,
RA   Abrams L.J., Graham J.M. Jr., Feingold M., Moeschler J.B.,
RA   Rawnsley E., Scott A.F., Jabs E.W.;
RT   "FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and
RT   Pfeiffer syndromes: evidence for missense changes, insertions, and a
RT   deletion due to alternative RNA splicing.";
RL   Am. J. Hum. Genet. 58:491-498(1996).
RN   [37]
RP   VARIANTS CS CYS-105; GLU-338; CYS-351 AND ARG-384.
RX   MEDLINE=97101656; PubMed=8946174;
RA   Pulleyn L.J., Reardon W., Wilkes D., Rutland P., Jones B.M.,
RA   Hayward R., Hall C.M., Brueton L., Chun N., Lammer E., Malcolm S.,
RA   Winter R.M.;
RT   "Spectrum of craniosynostosis phenotypes associated with novel
RT   mutations at the fibroblast growth factor receptor 2 locus.";
RL   Eur. J. Hum. Genet. 4:283-291(1996).
RN   [38]
RP   VARIANTS CS ILE-331; ASN-ALA-337 INS AND 356-TRP--THR-358 DEL.
RX   MEDLINE=97114301; PubMed=8956050;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:4<386::AID-HUMU18>3.3.CO;2-A;
RA   Steinberger D., Mulliken J.B., Mueller U.;
RT   "Crouzon syndrome: previously unrecognized deletion, duplication, and
RT   point mutation within FGFR2 gene.";
RL   Hum. Mutat. 8:386-390(1996).
RN   [39]
RP   VARIANTS BSCGS CYS-372 AND CYS-375.
RX   MEDLINE=96331296; PubMed=8696350; DOI=10.1038/ng0896-492;
RA   Przylepa K.A., Paznekas W.A., Zhang M., Golabi M., Bias W.,
RA   Bamshad M.J., Carey J.C., Hall B.D., Stevenson R., Orlow S.J.,
RA   Cohen M.M. Jr., Jabs E.W.;
RT   "Fibroblast growth factor receptor 2 mutations in Beare-Stevenson
RT   cutis gyrata syndrome.";
RL   Nat. Genet. 13:492-494(1996).
RN   [40]
RP   VARIANT PS CYS-290.
RX   MEDLINE=97295073; PubMed=9150725; DOI=10.1007/s004390050413;
RA   Tartaglia M., Valeri S., Velardi F., di Rocco C., Battaglia P.A.;
RT   "Trp290Cys mutation in exon IIIa of the fibroblast growth factor
RT   receptor 2 (FGFR2) gene is associated with Pfeiffer syndrome.";
RL   Hum. Genet. 99:602-606(1997).
RN   [41]
RP   VARIANT JWS SER-342.
RX   MEDLINE=98046343; PubMed=9385368; DOI=10.1007/s004390050584;
RA   Tartaglia M., Di Rocco C., Lajeunie E., Valeri S., Velardi F.,
RA   Battaglia P.A.;
RT   "Jackson-Weiss syndrome: identification of two novel FGFR2 missense
RT   mutations shared with Crouzon and Pfeiffer craniosynostotic
RT   disorders.";
RL   Hum. Genet. 101:47-50(1997).
RN   [42]
RP   VARIANT CS LEU-252, VARIANT APRS PHE-252, AND VARIANT PS
RP   252-PHE-SER-253.
RX   MEDLINE=97156222; PubMed=9002682; DOI=10.1093/hmg/6.1.137;
RA   Oldridge M., Lunt P.W., Zackai E.H., McDonald-Mcginn D.M., Muenke M.,
RA   Moloney D.M., Twigg S.R.F., Heath J.K., Howard T.D., Hoganson G.,
RA   Gagnon D.M., Jabs E.W., Wilkie A.O.M.;
RT   "Genotype-phenotype correlation for nucleotide substitutions in the
RT   IgII-IgIII linker of FGFR2.";
RL   Hum. Mol. Genet. 6:137-143(1997).
RN   [43]
RP   VARIANT CS GLU-292.
RX   MEDLINE=97297373; PubMed=9152842;
RA   Steinberger D., Collmann H., Schmalenberger B., Mueller U.;
RT   "A novel mutation (a886g) in exon 5 of FGFR2 in members of a family
RT   with Crouzon phenotype and plagiocephaly.";
RL   J. Med. Genet. 34:420-422(1997).
RN   [44]
RP   VARIANTS CS PHE-278; PRO-337; ARG-338; ARG-342; PHE-342 AND TYR-342,
RP   VARIANTS APRS TRP-252 AND ARG-253, AND VARIANT JWS PHE-278.
RX   MEDLINE=98339711; PubMed=9677057;
RX   DOI=10.1002/(SICI)1096-8628(19980707)78:3<237::AID-AJMG5>3.3.CO;2-5;
RA   Passos-Bueno M.R., Sertie A.L., Richieri-Costa A., Alonso L.G.,
RA   Zatz M., Alonso N., Brunoni D., Ribeiro S.F.M.;
RT   "Description of a new mutation and characterization of FGFR1, FGFR2,
RT   and FGFR3 mutations among Brazilian patients with syndromic
RT   craniosynostoses.";
RL   Am. J. Med. Genet. 78:237-241(1998).
RN   [45]
RP   VARIANTS CS VAL-276 AND CYS-301, AND VARIANT CRANIOSYNOSTOSIS SER-314.
RX   MEDLINE=98180879; PubMed=9521581; DOI=10.1007/s004390050668;
RA   Steinberger D., Vriend G., Mulliken J.B., Mueller U.;
RT   "The mutations in FGFR2-associated craniosynostoses are clustered in
RT   five structural elements of immunoglobulin-like domain III of the
RT   receptor.";
RL   Hum. Genet. 102:145-150(1998).
RN   [46]
RP   VARIANTS APRS TRP-252 AND ARG-253.
RX   MEDLINE=98112406; PubMed=9452027;
RA   Tsai F.-J., Hwu W.-L., Lin S.-P., Chang J.-G., Wang T.-R., Tsai C.-H.;
RT   "Two common mutations 934C to G and 937C to G of fibroblast growth
RT   factor receptor 2 (FGFR2) gene in Chinese patients with Apert
RT   syndrome.";
RL   Hum. Mutat. Suppl. 1:S18-S19(1998).
RN   [47]
RP   VARIANT PS CYS-351.
RX   MEDLINE=98358420; PubMed=9693549;
RA   Mathijssen I.M., Vaandrager J.M., Hoogeboom A.J.,
RA   Hesseling-Janssen A.L.W., van den Ouweland A.M.W.;
RT   "Pfeiffer's syndrome resulting from an S351C mutation in the
RT   fibroblast growth factor receptor-2 gene.";
RL   J. Craniofac. Surg. 9:207-209(1998).
RN   [48]
RP   VARIANT PS TRP-252.
RX   MEDLINE=98383883; PubMed=9719378;
RA   Passos-Bueno M.R., Richieri-Costa A., Sertie A.L., Kneppers A.;
RT   "Presence of the Apert canonical S252W FGFR2 mutation in a patient
RT   without severe syndactyly.";
RL   J. Med. Genet. 35:677-679(1998).
RN   [49]
RP   VARIANT CS SER-362.
RX   MEDLINE=20039830; PubMed=10574673;
RA   Everett E.T., Britto D.A., Ward R.E., Hartsfield J.K. Jr.;
RT   "A novel FGFR2 gene mutation in Crouzon syndrome associated with
RT   apparent nonpenetrance.";
RL   Cleft Palate Craniofac. J. 36:533-541(1999).
RN   [50]
RP   VARIANTS PS CYS-340 AND GLY-342.
RX   MEDLINE=99320859; PubMed=10394936; DOI=10.1007/s004390050979;
RA   Cornejo-Roldan L.R., Roessler E., Muenke M.;
RT   "Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer
RT   syndrome.";
RL   Hum. Genet. 104:425-431(1999).
RN   [51]
RP   VARIANT PS ASP-273 DEL.
RX   MEDLINE=20399766; PubMed=10945669;
RX   DOI=10.1034/j.1399-0004.2000.580116.x;
RA   Priolo M., Lerone M., Baffico M., Baldi M., Ravazzolo R., Cama A.,
RA   Capra V., Silengo M.;
RT   "Pfeiffer syndrome type 2 associated with a single amino acid deletion
RT   in the FGFR2 gene.";
RL   Clin. Genet. 58:81-83(2000).
RN   [52]
RP   VARIANTS CS/PS ARG-342 AND TYR-342, VARIANTS CS LEU-263; VAL-276;
RP   PHE-278; TYR-278; SER-288; PRO-289; PRO-341; TRP-342; CYS-354; TYR-354
RP   AND PHE-359, AND VARIANT PS SER-342.
RX   MEDLINE=21098463; PubMed=11173845;
RA   Kress W., Collmann H., Buesse M., Halliger-Keller B., Mueller C.R.;
RT   "Clustering of FGFR2 gene mutations inpatients with Pfeiffer and
RT   Crouzon syndromes (FGFR2-associated craniosynostoses).";
RL   Cytogenet. Cell Genet. 91:134-137(2000).
RN   [53]
RP   VARIANT SER-315.
RX   MEDLINE=20410879; PubMed=10951518; DOI=10.1038/sj.ejhg.5200499;
RA   Johnson D., Wall S.A., Mann S., Wilkie A.O.M.;
RT   "A novel mutation, Ala315Ser, in FGFR2: a gene-environment interaction
RT   leading to craniosynostosis?";
RL   Eur. J. Hum. Genet. 8:571-577(2000).
RN   [54]
RP   VARIANTS ABS ARG-342; SER-342 AND CYS-351.
RX   PubMed=10633130; DOI=10.1136/jmg.37.1.26;
RA   Reardon W., Smith A., Honour J.W., Hindmarsh P., Das D., Rumsby G.,
RA   Nelson I., Malcolm S., Ades L., Sillence D., Kumar D.,
RA   DeLozier-Blanchet C., McKee S., Kelly T., McKeehan W.L., Baraitser M.,
RA   Winter R.M.;
RT   "Evidence for digenic inheritance in some cases of Antley-Bixler
RT   syndrome?";
RL   J. Med. Genet. 37:26-32(2000).
RN   [55]
RP   VARIANTS CS CYS-281; PRO-289; ARG-342 AND TYR-342.
RX   MEDLINE=21276016; PubMed=11380921;
RX   DOI=10.1046/j.1442-200x.2001.01392.x;
RA   Tsai F.-J., Yang C.-F., Wu J.-Y., Tsai C.-H., Lee C.-C.;
RT   "Mutation analysis of Crouzon syndrome and identification of one novel
RT   mutation in Taiwanese patients.";
RL   Pediatr. Int. 43:263-266(2001).
RN   [56]
RP   VARIANTS CS CYS-105; PRO-267; VAL-276; CYS-281; PRO-289; ARG-338;
RP   HIS-340; PHE-342; TRP-342; CYS-347; CYS-354; HIS-549 AND GLY-678,
RP   VARIANTS PS PHE-172; 252-PHE-SER-253; CYS-290; CYS-340; PRO-341;
RP   ARG-342; SER-342; CYS-375; GLY-565; ARG-641 AND GLU-663, VARIANTS APRS
RP   TRP-252 AND ARG-253, VARIANTS CS/PS PHE-278 AND TYR-342, VARIANT
RP   CRANIOSYNOSTOSIS ASN-659, AND VARIANTS THR-186 AND SER-315.
RX   MEDLINE=21649972; PubMed=11781872; DOI=10.1086/338758;
RA   Kan S.-H., Elanko N., Johnson D., Cornejo-Roldan L.R., Cook J.,
RA   Reich E.W., Tomkins S., Verloes A., Twigg S.R.F., Rannan-Eliya S.,
RA   McDonald-McGinn D.M., Zackai E.H., Wall S.A., Muenke M.,
RA   Wilkie A.O.M.;
RT   "Genomic screening of fibroblast growth-factor receptor 2 reveals a
RT   wide spectrum of mutations in patients with syndromic
RT   craniosynostosis.";
RL   Am. J. Hum. Genet. 70:472-486(2002).
RN   [57]
RP   VARIANT BSCGS CYS-375.
RX   MEDLINE=21995979; PubMed=12000365;
RX   DOI=10.1034/j.1399-0004.2002.610309.x;
RA   Wang T.-J., Huang C.-B., Tsai F.-J., Wu J.-Y., Lai R.-B., Hsiao M.;
RT   "Mutation in the FGFR2 gene in a Taiwanese patient with Beare-
RT   Stevenson cutis gyrata syndrome.";
RL   Clin. Genet. 61:218-221(2002).
RN   [58]
RP   VARIANT FSPC GLU-526.
RX   PubMed=16061565; DOI=10.1136/jmg.2004.027888;
RA   McGillivray G., Savarirayan R., Cox T.C., Stojkoski C., McNeil R.,
RA   Bankier A., Bateman J.F., Roscioli T., Gardner R.J.M., Lamande S.R.;
RT   "Familial scaphocephaly syndrome caused by a novel mutation in the
RT   FGFR2 tyrosine kinase domain.";
RL   J. Med. Genet. 42:656-662(2005).
RN   [59]
RP   VARIANTS LADDS THR-628; THR-648 AND 649-ARG-ASP-650 DELINS SER.
RX   PubMed=16501574; DOI=10.1038/ng1757;
RA   Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G.,
RA   Lew E.D., Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M.,
RA   Leroy J.G., Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J.,
RA   Yueksel-Apak M., Nuernberg P., Kubisch C., Schlessinger J.,
RA   van Bokhoven H., Wollnik B.;
RT   "Mutations in different components of FGF signaling in LADD
RT   syndrome.";
RL   Nat. Genet. 38:414-417(2006).
RN   [60]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-203.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [61]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-57; THR-186; CYS-203; VAL-272;
RP   ASN-283; CYS-290 AND THR-612.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor for acidic and basic fibroblast growth factors.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- INTERACTION:
CC       P05230:FGF1; NbExp=1; IntAct=EBI-1028658, EBI-698068;
CC       O15520:FGF10; NbExp=1; IntAct=EBI-1028658, EBI-1035684;
CC       P09038:FGF2; NbExp=1; IntAct=EBI-1028658, EBI-977447;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 14: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 19: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=20;
CC       Name=1; Synonyms=BEK;
CC         IsoId=P21802-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P21802-2; Sequence=VSP_002978;
CC       Name=3; Synonyms=BFR-1;
CC         IsoId=P21802-3; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                  VSP_002972;
CC       Name=4; Synonyms=K-sam;
CC         IsoId=P21802-4; Sequence=VSP_002964, VSP_002969, VSP_002970,
CC                                  VSP_002971, VSP_002972, VSP_002975,
CC                                  VSP_002976;
CC       Name=5; Synonyms=K-sam-I, BEK, IgIIIc;
CC         IsoId=P21802-5; Sequence=VSP_002975;
CC       Name=6; Synonyms=K-sam-IIC2;
CC         IsoId=P21802-6; Sequence=VSP_002975, VSP_002984;
CC       Name=7; Synonyms=K-sam-IIO2;
CC         IsoId=P21802-7; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                  VSP_002972, VSP_002979;
CC       Name=8; Synonyms=K-sam-IIC3;
CC         IsoId=P21802-8; Sequence=VSP_002975, VSP_002978;
CC       Name=9; Synonyms=K-sam-IIH1;
CC         IsoId=P21802-9; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                  VSP_002972, VSP_002980;
CC       Name=10; Synonyms=K-sam-IIH2;
CC         IsoId=P21802-10; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002981;
CC       Name=11; Synonyms=K-sam-IIH3, K-sam-IIO4;
CC         IsoId=P21802-11; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002982;
CC       Name=12; Synonyms=K-sam-IIO1;
CC         IsoId=P21802-12; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002983;
CC       Name=13; Synonyms=K-sam-IIO3;
CC         IsoId=P21802-13; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002977;
CC       Name=14; Synonyms=K-sam-IV, Soluble KGFR;
CC         IsoId=P21802-14; Sequence=VSP_002965, VSP_002966;
CC       Name=15; Synonyms=K-sam-III;
CC         IsoId=P21802-15; Sequence=VSP_002968;
CC       Name=16; Synonyms=TK14;
CC         IsoId=P21802-16; Sequence=VSP_002967, VSP_002975;
CC       Name=17;
CC         IsoId=P21802-17; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002978;
CC       Name=18; Synonyms=K-sam-IIC1, KGFR, IgIIIb;
CC         IsoId=P21802-18; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002975;
CC       Name=19; Synonyms=Soluble KGFR;
CC         IsoId=P21802-19; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002973, VSP_002974;
CC       Name=20;
CC         IsoId=P21802-20; Sequence=VSP_019608, VSP_019609;
CC   -!- DISEASE: Defects in FGFR2 are the cause of Crouzon syndrome (CS)
CC       [MIM:123500]; also called craniofacial dysostosis type I (CFD1).
CC       CS is an autosomal dominant syndrome characterized by
CC       craniosynostosis (premature fusion of the skull sutures),
CC       hypertelorism, exophthalmos and external strabismus, parrot-beaked
CC       nose, short upper lip, hypoplastic maxilla, and a relative
CC       mandibular prognathism.
CC   -!- DISEASE: Defects in FGFR2 are a cause of Jackson-Weiss syndrome
CC       (JWS) [MIM:123150]. JWS is an autosomal dominant craniosynostosis
CC       syndrome characterized by craniofacial abnormalities and
CC       abnormality of the feet: broad great toes with medial deviation
CC       and tarsal-metatarsal coalescence.
CC   -!- DISEASE: Defects in FGFR2 are a cause of Apert syndrome (APRS)
CC       [MIM:101200]; also known as acrocephalosyndactyly type 1 (ACS1).
CC       APRS is a syndrome characterized by facio-cranio-synostosis,
CC       osseous and membranous syndactyly of the four extremities, and
CC       midface hypoplasia. The craniosynostosis is bicoronal and results
CC       in acrocephaly of brachysphenocephalic type. Syndactyly of the
CC       fingers and toes may be total (mitten hands and sock feet) or
CC       partial affecting the second, third, and fourth digits.
CC       Intellectual deficit is frequent and often severe, usually being
CC       associated with cerebral malformations.
CC   -!- DISEASE: Defects in FGFR2 are a cause of Pfeiffer syndrome (PS)
CC       [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5).
CC       PS is characterized by craniosynostosis (premature fusion of the
CC       skull sutures) with deviation and enlargement of the thumbs and
CC       great toes, brachymesophalangy, with phalangeal ankylosis and a
CC       varying degree of soft tissue syndactyly. Three subtypes of
CC       Pfeiffer syndrome have been described: mild autosomal dominant
CC       form (type 1); cloverleaf skull, elbow ankylosis, early death,
CC       sporadic (type 2); craniosynostosis, early demise, sporadic (type
CC       3).
CC   -!- DISEASE: Defects in FGFR2 are the cause of Beare-Stevenson cutis
CC       gyrata syndrome (BSCGS) [MIM:123790]. BSCGS is an autosomal
CC       dominant condition is characterized by the furrowed skin disorder
CC       of cutis gyrata, acanthosis nigricans, craniosynostosis,
CC       craniofacial dysmorphism, digital anomalies, umbilical and
CC       anogenital abnormalities and early death.
CC   -!- DISEASE: Defects in FGFR2 are the cause of familial scaphocephaly
CC       syndrome (FSPC) [MIM:609579]; also known as scaphocephaly with
CC       maxillary retrusion and mental retardation. FSPC is an autosomal
CC       dominant craniosynostosis syndrome characterized by scaphocephaly,
CC       macrocephaly, hypertelorism, maxillary retrusion, and mild
CC       intellectual disability. Scaphocephaly is the most common of the
CC       craniosynostosis conditions and is characterized by a long, narrow
CC       head. It is due to premature fusion of the sagittal suture or from
CC       external deformation.
CC   -!- DISEASE: Defects in FGFR2 are a cause of lacrimo-auriculo-dento-
CC       digital syndrome (LADDS) [MIM:149730]; also known as Levy-
CC       Hollister syndrome. LADDS is a form of ectodermal dysplasia, a
CC       heterogeneous group of disorders due to abnormal development of
CC       two or more ectodermal structures. LADDS is an autosomal dominant
CC       syndrome characterized by aplastic/hypoplastic lacrimal and
CC       salivary glands and ducts, cup-shaped ears, hearing loss,
CC       hypodontia and enamel hypoplasia, and distal limb segments
CC       anomalies. In addition to these cardinal features, facial
CC       dysmorphism, malformations of the kidney and respiratory system
CC       and abnormal genitalia have been reported. Craniosynostosis and
CC       severe syndactyly are not observed.
CC   -!- DISEASE: Defects in FGFR2 are the cause of Antley-Bixler syndrome
CC       (ABS) [MIM:207410]. ABS is a multiple congenital anomaly syndrome
CC       characterized by craniosynostosis, radiohumeral synostosis,
CC       midface hypoplasia, malformed ears, arachnodactyly and multiple
CC       joint contractures. ABS is a heterogeneous disorder and occurs
CC       with and without abnormal genitalia in both sexes.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC   -!- SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFR2ID40570ch10q26.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/FGFR2";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52832; CAA37014.1; -; mRNA.
DR   EMBL; M55614; AAA61188.1; -; mRNA.
DR   EMBL; X56191; CAA39654.1; -; mRNA.
DR   EMBL; M35718; AAA36152.1; -; mRNA.
DR   EMBL; M87770; AAA59470.1; -; mRNA.
DR   EMBL; M87771; AAA59471.1; -; mRNA.
DR   EMBL; M87772; AAA59472.1; -; mRNA.
DR   EMBL; M97193; AAA52449.1; -; mRNA.
DR   EMBL; U11814; AAA68514.1; -; mRNA.
DR   EMBL; M80634; AAA36147.1; -; mRNA.
DR   EMBL; Z71929; CAA96492.1; -; mRNA.
DR   EMBL; AB030073; BAA89296.1; -; mRNA.
DR   EMBL; AB030074; BAA89297.1; -; mRNA.
DR   EMBL; AB030075; BAA89298.1; -; mRNA.
DR   EMBL; AB030076; BAA89299.1; -; mRNA.
DR   EMBL; AB030077; BAA89300.1; -; mRNA.
DR   EMBL; AB030078; BAA89301.1; -; mRNA.
DR   EMBL; AF360695; AAK94205.1; -; Genomic_DNA.
DR   EMBL; AF410480; AAK94205.1; JOINED; Genomic_DNA.
DR   EMBL; AF360695; AAK94206.1; -; Genomic_DNA.
DR   EMBL; AF410480; AAK94206.1; JOINED; Genomic_DNA.
DR   EMBL; AF360695; AAK94207.1; -; Genomic_DNA.
DR   EMBL; AF410480; AAK94207.1; JOINED; Genomic_DNA.
DR   EMBL; AF360695; AAK94208.1; -; Genomic_DNA.
DR   EMBL; AF410480; AAK94208.1; JOINED; Genomic_DNA.
DR   EMBL; AF360695; AAK94209.1; -; Genomic_DNA.
DR   EMBL; AF410480; AAK94209.1; JOINED; Genomic_DNA.
DR   EMBL; AF487553; AAM74056.1; -; Genomic_DNA.
DR   EMBL; DQ493927; ABE96832.1; -; Genomic_DNA.
DR   EMBL; BC039243; AAH39243.2; -; mRNA.
DR   EMBL; AF169399; AAF43273.1; -; Genomic_DNA.
DR   EMBL; AF169399; AAF43274.1; -; Genomic_DNA.
DR   EMBL; AF097353; AAD31560.1; -; Genomic_DNA.
DR   EMBL; AF097341; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097342; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097343; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097345; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097346; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097347; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097348; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097349; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097350; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097351; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097352; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097353; AAD31561.1; -; Genomic_DNA.
DR   EMBL; AF097341; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097342; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097344; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097345; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097346; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097347; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097348; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097349; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097350; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097351; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097352; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097340; AAD31562.1; -; Genomic_DNA.
DR   EMBL; AF097337; AAD31562.1; JOINED; Genomic_DNA.
DR   EMBL; AF097338; AAD31562.1; JOINED; Genomic_DNA.
DR   EMBL; AF097339; AAD31562.1; JOINED; Genomic_DNA.
DR   EMBL; AF097354; AAD31565.1; -; Genomic_DNA.
DR   EMBL; AF097341; AAD31567.1; -; Genomic_DNA.
DR   EMBL; S82438; AAD14392.1; -; Genomic_DNA.
DR   EMBL; Y17131; CAA76643.1; -; Genomic_DNA.
DR   EMBL; L49237; AAC41933.1; -; Genomic_DNA.
DR   EMBL; L49242; AAC41934.1; -; Genomic_DNA.
DR   EMBL; L49238; AAC41935.1; -; Genomic_DNA.
DR   EMBL; L49239; AAC41936.1; -; Genomic_DNA.
DR   EMBL; L49240; AAC41937.1; -; Genomic_DNA.
DR   EMBL; L49241; AAC41938.1; -; Genomic_DNA.
DR   IPI; IPI00010680; -.
DR   IPI; IPI00216602; -.
DR   IPI; IPI00216603; -.
DR   IPI; IPI00216604; -.
DR   IPI; IPI00216605; -.
DR   IPI; IPI00218416; -.
DR   IPI; IPI00218417; -.
DR   IPI; IPI00218418; -.
DR   IPI; IPI00218419; -.
DR   IPI; IPI00218420; -.
DR   IPI; IPI00218421; -.
DR   IPI; IPI00218422; -.
DR   IPI; IPI00218423; -.
DR   IPI; IPI00218425; -.
DR   IPI; IPI00384713; -.
DR   IPI; IPI00386650; -.
DR   IPI; IPI00647907; -.
DR   IPI; IPI00759837; -.
DR   IPI; IPI00873362; -.
DR   IPI; IPI00942110; -.
DR   PIR; A35969; A35969.
DR   PIR; A42691; TVHUF2.
DR   PIR; A45081; A45081.
DR   PIR; C42691; C42691.
DR   PIR; S16236; S16236.
DR   RefSeq; NP_000132.3; -.
DR   RefSeq; NP_001138385.1; -.
DR   RefSeq; NP_001138386.1; -.
DR   RefSeq; NP_001138387.1; -.
DR   RefSeq; NP_001138388.1; -.
DR   RefSeq; NP_001138389.1; -.
DR   RefSeq; NP_001138390.1; -.
DR   RefSeq; NP_001138391.1; -.
DR   RefSeq; NP_075259.4; -.
DR   UniGene; Hs.533683; -.
DR   PDB; 1DJS; X-ray; 2.40 A; A=153-362.
DR   PDB; 1E0O; X-ray; 2.80 A; B/D=148-366.
DR   PDB; 1EV2; X-ray; 2.20 A; E/F/G/H=147-366.
DR   PDB; 1GJO; X-ray; 2.40 A; A=456-768.
DR   PDB; 1II4; X-ray; 2.70 A; E/F/G/H=147-366.
DR   PDB; 1IIL; X-ray; 2.30 A; E/F/G/H=147-366.
DR   PDB; 1NUN; X-ray; 2.90 A; B=140-361.
DR   PDB; 1OEC; X-ray; 2.40 A; A=456-768.
DR   PDB; 1WVZ; NMR; -; A=147-249.
DR   PDB; 2FDB; X-ray; 2.28 A; P/R=149-368.
DR   PDB; 2PSQ; X-ray; 2.40 A; A/B=413-768.
DR   PDB; 2PVF; X-ray; 1.80 A; A=458-778, B=764-778.
DR   PDB; 2PVY; X-ray; 2.20 A; A/B/C/D=458-768.
DR   PDB; 2PWL; X-ray; 2.40 A; A/B=458-768.
DR   PDB; 2PY3; X-ray; 2.30 A; A/B=458-768.
DR   PDB; 2PZ5; X-ray; 2.40 A; A/B=458-768.
DR   PDB; 2PZP; X-ray; 2.40 A; A/B=458-768.
DR   PDB; 2PZR; X-ray; 3.00 A; A/B=458-768.
DR   PDB; 2Q0B; X-ray; 2.90 A; A/B=458-768.
DR   PDB; 3B2T; X-ray; 1.80 A; A/B=458-766.
DR   PDB; 3CAF; X-ray; 1.96 A; A=150-249.
DR   PDB; 3CLY; X-ray; 2.00 A; A=458-778.
DR   PDB; 3CU1; X-ray; 2.60 A; A/C=150-249.
DR   PDB; 3DAR; X-ray; 2.20 A; A/B=146-249.
DR   PDB; 3EUU; X-ray; 2.34 A; A/B=150-249.
DR   PDBsum; 1DJS; -.
DR   PDBsum; 1E0O; -.
DR   PDBsum; 1EV2; -.
DR   PDBsum; 1GJO; -.
DR   PDBsum; 1II4; -.
DR   PDBsum; 1IIL; -.
DR   PDBsum; 1NUN; -.
DR   PDBsum; 1OEC; -.
DR   PDBsum; 1WVZ; -.
DR   PDBsum; 2FDB; -.
DR   PDBsum; 2PSQ; -.
DR   PDBsum; 2PVF; -.
DR   PDBsum; 2PVY; -.
DR   PDBsum; 2PWL; -.
DR   PDBsum; 2PY3; -.
DR   PDBsum; 2PZ5; -.
DR   PDBsum; 2PZP; -.
DR   PDBsum; 2PZR; -.
DR   PDBsum; 2Q0B; -.
DR   PDBsum; 3B2T; -.
DR   PDBsum; 3CAF; -.
DR   PDBsum; 3CLY; -.
DR   PDBsum; 3CU1; -.
DR   PDBsum; 3DAR; -.
DR   PDBsum; 3EUU; -.
DR   ProteinModelPortal; P21802; -.
DR   SMR; P21802; 44-125, 49-357, 479-792.
DR   DIP; DIP-3788N; -.
DR   DIP; DIP-4011N; -.
DR   IntAct; P21802; 7.
DR   MINT; MINT-118359; -.
DR   STRING; P21802; -.
DR   PhosphoSite; P21802; -.
DR   PRIDE; P21802; -.
DR   Ensembl; ENST00000357555; ENSP00000350166; ENSG00000066468.
DR   Ensembl; ENST00000358487; ENSP00000351276; ENSG00000066468.
DR   GeneID; 2263; -.
DR   KEGG; hsa:2263; -.
DR   UCSC; uc001lfj.2; human.
DR   UCSC; uc001lfm.1; human.
DR   UCSC; uc001lfo.1; human.
DR   UCSC; uc009xzo.1; human.
DR   UCSC; uc009xzp.1; human.
DR   UCSC; uc009xzq.1; human.
DR   UCSC; uc009xzr.1; human.
DR   CTD; 2263; -.
DR   GeneCards; GC10M123223; -.
DR   H-InvDB; HIX0009266; -.
DR   HGNC; HGNC:3689; FGFR2.
DR   HPA; CAB010886; -.
DR   MIM; 101200; phenotype.
DR   MIM; 101600; phenotype.
DR   MIM; 123150; phenotype.
DR   MIM; 123500; phenotype.
DR   MIM; 123790; phenotype.
DR   MIM; 149730; phenotype.
DR   MIM; 176943; gene.
DR   MIM; 207410; phenotype.
DR   MIM; 609579; phenotype.
DR   Orphanet; 83; Antley-Bixler syndrome.
DR   Orphanet; 87; Apert syndrome.
DR   Orphanet; 207; Crouzon disease.
DR   Orphanet; 1555; Cutis gyrata - acanthosis nigricans - craniosynostosis.
DR   Orphanet; 168624; Familial scaphocephaly syndrome, McGillivray type.
DR   Orphanet; 1540; Jackson-Weiss syndrome.
DR   Orphanet; 2363; Lacrimo-auriculo-dento-digital syndrome.
DR   Orphanet; 93258; Pfeiffer syndrome type 1.
DR   Orphanet; 93259; Pfeiffer syndrome type 2.
DR   Orphanet; 93260; Pfeiffer syndrome type 3.
DR   PharmGKB; PA28128; -.
DR   eggNOG; prNOG07516; -.
DR   HOVERGEN; HBG000345; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; fgf_pathway; FGF signaling pathway.
DR   Reactome; REACT_498; Signaling by Insulin receptor.
DR   Reactome; REACT_9470; Signaling by FGFR.
DR   DrugBank; DB00039; Palifermin.
DR   ArrayExpress; P21802; -.
DR   Bgee; P21802; -.
DR   Genevestigator; P21802; -.
DR   GermOnline; ENSG00000066468; Homo sapiens.
DR   GO; GO:0005938; C:cell cortex; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; NAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; EXP:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IPI:MGI.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IPI:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor receptor activity; NAS:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0016049; P:cell growth; NAS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IGI:MGI.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; NAS:UniProtKB.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020933; Tyr_kin_fibroblast_GF_rcpt_reg.
DR   InterPro; IPR016248; Tyr_kinase_fibroblast_GF_rcpt.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 3.
DR   PANTHER; PTHR23256:SF276; Tyr_kinase_fibroblast_GF_rcpt; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Craniosynostosis; Disease mutation; Disulfide bond;
KW   Ectodermal dysplasia; Glycoprotein; Heparin-binding;
KW   Immunoglobulin domain; Kinase;
KW   Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Repeat; Secreted; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     21       Potential.
FT   CHAIN        22    821       Fibroblast growth factor receptor 2.
FT                                /FTId=PRO_0000016783.
FT   TOPO_DOM     22    377       Extracellular (Potential).
FT   TRANSMEM    378    398       Helical; (Potential).
FT   TOPO_DOM    399    821       Cytoplasmic (Potential).
FT   DOMAIN       25    125       Ig-like C2-type 1.
FT   DOMAIN      154    247       Ig-like C2-type 2.
FT   DOMAIN      256    358       Ig-like C2-type 3.
FT   DOMAIN      481    770       Protein kinase.
FT   NP_BIND     487    495       ATP (By similarity).
FT   REGION      161    178       Heparin-binding.
FT   ACT_SITE    626    626       Proton acceptor (By similarity).
FT   BINDING     517    517       ATP (By similarity).
FT   MOD_RES     448    448       Phosphothreonine.
FT   MOD_RES     449    449       Phosphothreonine.
FT   MOD_RES     657    657       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   CARBOHYD     83     83       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    123    123       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    228    228       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    241    241       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    265    265       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    297    297       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    318    318       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    331    331       N-linked (GlcNAc...) (Potential).
FT   DISULFID     62    107       Potential.
FT   DISULFID    179    231       Potential.
FT   DISULFID    278    342       Potential.
FT   VAR_SEQ      37    152       EPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGV
FT                                HLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETW
FT                                YFMVNVTDAISSGDDEDDTDGAEDFVSENSNNKR -> G
FT                                (in isoform 20).
FT                                /FTId=VSP_019608.
FT   VAR_SEQ      37    125       Missing (in isoform 4).
FT                                /FTId=VSP_002964.
FT   VAR_SEQ     250    254       ERSPH -> GSQGL (in isoform 14).
FT                                /FTId=VSP_002965.
FT   VAR_SEQ     255    821       Missing (in isoform 14).
FT                                /FTId=VSP_002966.
FT   VAR_SEQ     313    313       K -> KVLK (in isoform 16).
FT                                /FTId=VSP_002967.
FT   VAR_SEQ     314    429       Missing (in isoform 15).
FT                                /FTId=VSP_002968.
FT   VAR_SEQ     314    330       AAGVNTTDKEIEVLYIR -> HSGINSSNAEVLALF (in
FT                                isoform 3, isoform 4, isoform 7, isoform
FT                                9, isoform 10, isoform 11, isoform 12,
FT                                isoform 13, isoform 17, isoform 18 and
FT                                isoform 19).
FT                                /FTId=VSP_002969.
FT   VAR_SEQ     334    335       FE -> EA (in isoform 3, isoform 4,
FT                                isoform 7, isoform 9, isoform 10, isoform
FT                                11, isoform 12, isoform 13, isoform 17,
FT                                isoform 18 and isoform 19).
FT                                /FTId=VSP_002970.
FT   VAR_SEQ     341    353       TCLAGNSIGISFH -> ICKVSNYIGQANQ (in
FT                                isoform 3, isoform 4, isoform 7, isoform
FT                                9, isoform 10, isoform 11, isoform 12,
FT                                isoform 13, isoform 17, isoform 18 and
FT                                isoform 19).
FT                                /FTId=VSP_002971.
FT   VAR_SEQ     361    361       P -> PKQQ (in isoform 3, isoform 4,
FT                                isoform 7, isoform 9, isoform 10, isoform
FT                                11, isoform 12, isoform 13, isoform 17,
FT                                isoform 18 and isoform 19).
FT                                /FTId=VSP_002972.
FT   VAR_SEQ     362    365       APGR -> GRRC (in isoform 19).
FT                                /FTId=VSP_002973.
FT   VAR_SEQ     366    821       Missing (in isoform 19).
FT                                /FTId=VSP_002974.
FT   VAR_SEQ     428    429       Missing (in isoform 4, isoform 5, isoform
FT                                6, isoform 8, isoform 16 and isoform 18).
FT                                /FTId=VSP_002975.
FT   VAR_SEQ     429    430       Missing (in isoform 20).
FT                                /FTId=VSP_019609.
FT   VAR_SEQ     761    821       LTLTTNEEYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPD
FT                                PMPYEPCLPQYPHINGSVKT -> PPNPSLMSIFRK (in
FT                                isoform 4).
FT                                /FTId=VSP_002976.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> SFQSSLKSSSTGIPGWPPGSEVFS
FT                                EVAFRGILNYDIERPILCAGSKKIYDI (in isoform
FT                                10).
FT                                /FTId=VSP_002981.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> GRLPAWASQEKENSQTSLFAISHV
FT                                TLSSISKTRSSAKRDEKPGSSPHLALVRSQGLPQSVVP
FT                                (in isoform 11).
FT                                /FTId=VSP_002982.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> PLS (in isoform 12).
FT                                /FTId=VSP_002983.
FT   VAR_SEQ     768    821       Missing (in isoform 13).
FT                                /FTId=VSP_002977.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> I (in isoform 2, isoform
FT                                8 and isoform 17).
FT                                /FTId=VSP_002978.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> RYKLLPCPDKHNKRCKPEERGDLT
FT                                EAGAAGSSRCVDSRKRVRQEKISTG (in isoform 7).
FT                                /FTId=VSP_002979.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> RILTLTTNENFQSTSGREGTEIHA
FT                                LQCLRSEVTPAISCESPLADTGSKVPN (in isoform
FT                                9).
FT                                /FTId=VSP_002980.
FT   VAR_SEQ     778    821       QYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGS
FT                                VKT -> PYSPCYPDPR (in isoform 6).
FT                                /FTId=VSP_002984.
FT   VARIANT       6      6       R -> P (in dbSNP:rs3750819).
FT                                /FTId=VAR_017258.
FT   VARIANT      57     57       S -> L (in dbSNP:rs56226109).
FT                                /FTId=VAR_042204.
FT   VARIANT     105    105       Y -> C (in CS).
FT                                /FTId=VAR_004112.
FT   VARIANT     172    172       A -> F (in PS; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_017259.
FT   VARIANT     186    186       M -> T (in dbSNP:rs755793).
FT                                /FTId=VAR_017260.
FT   VARIANT     203    203       R -> C (in breast cancer samples;
FT                                infiltrating ductal carcinoma; somatic
FT                                mutation).
FT                                /FTId=VAR_036380.
FT   VARIANT     252    253       SP -> FS (in PS).
FT                                /FTId=VAR_004116.
FT   VARIANT     252    252       S -> F (in APRS; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_004114.
FT   VARIANT     252    252       S -> L (in CS).
FT                                /FTId=VAR_004113.
FT   VARIANT     252    252       S -> W (in APRS and PS; common mutation).
FT                                /FTId=VAR_004115.
FT   VARIANT     253    253       P -> R (in APRS; common mutation).
FT                                /FTId=VAR_004117.
FT   VARIANT     263    263       P -> L (in CS).
FT                                /FTId=VAR_017261.
FT   VARIANT     267    267       S -> P (in CS).
FT                                /FTId=VAR_004118.
FT   VARIANT     268    268       T -> TG (in CS).
FT                                /FTId=VAR_004119.
FT   VARIANT     272    272       G -> V (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042205.
FT   VARIANT     273    273       Missing (in PS; type 2).
FT                                /FTId=VAR_017262.
FT   VARIANT     276    276       F -> V (in CS).
FT                                /FTId=VAR_004120.
FT   VARIANT     278    278       C -> F (in CS, JWS and PS).
FT                                /FTId=VAR_004121.
FT   VARIANT     278    278       C -> Y (in CS).
FT                                /FTId=VAR_017263.
FT   VARIANT     281    281       Y -> C (in CS).
FT                                /FTId=VAR_017264.
FT   VARIANT     283    283       D -> N (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042206.
FT   VARIANT     287    289       Missing (in CS).
FT                                /FTId=VAR_004122.
FT   VARIANT     288    288       I -> S (in CS).
FT                                /FTId=VAR_017265.
FT   VARIANT     289    289       Q -> P (in CS and JWS).
FT                                /FTId=VAR_004123.
FT   VARIANT     290    290       W -> C (in PS; severe; also in a lung
FT                                squamous cell carcinoma sample; somatic
FT                                mutation).
FT                                /FTId=VAR_004124.
FT   VARIANT     290    290       W -> G (in CS).
FT                                /FTId=VAR_017266.
FT   VARIANT     290    290       W -> R (in CS).
FT                                /FTId=VAR_004125.
FT   VARIANT     292    292       K -> E (in CS).
FT                                /FTId=VAR_004126.
FT   VARIANT     301    301       Y -> C (in CS).
FT                                /FTId=VAR_004127.
FT   VARIANT     314    314       A -> S (in craniosynostosis).
FT                                /FTId=VAR_004128.
FT   VARIANT     315    315       A -> S (in a non-syndromic
FT                                craniosynostosis patient with abnormal
FT                                intrauterine history; confers
FT                                predisposition to craniosynostosis).
FT                                /FTId=VAR_017267.
FT   VARIANT     321    321       D -> A (in PS).
FT                                /FTId=VAR_004129.
FT   VARIANT     328    328       Y -> C (in CS).
FT                                /FTId=VAR_004130.
FT   VARIANT     331    331       N -> I (in CS).
FT                                /FTId=VAR_004131.
FT   VARIANT     337    337       A -> ANA (in CS).
FT                                /FTId=VAR_004132.
FT   VARIANT     337    337       A -> P (in CS).
FT                                /FTId=VAR_017268.
FT   VARIANT     338    338       G -> E (in CS).
FT                                /FTId=VAR_004133.
FT   VARIANT     338    338       G -> R (in CS).
FT                                /FTId=VAR_015011.
FT   VARIANT     340    340       Y -> C (in PS).
FT                                /FTId=VAR_017269.
FT   VARIANT     340    340       Y -> H (in CS).
FT                                /FTId=VAR_004134.
FT   VARIANT     341    341       T -> P (in PS and CS).
FT                                /FTId=VAR_004135.
FT   VARIANT     342    342       C -> F (in CS).
FT                                /FTId=VAR_004136.
FT   VARIANT     342    342       C -> G (in PS).
FT                                /FTId=VAR_017270.
FT   VARIANT     342    342       C -> R (in CS, JWS, PS and ABS).
FT                                /FTId=VAR_004137.
FT   VARIANT     342    342       C -> S (in CS, JWS, PS and ABS).
FT                                /FTId=VAR_004138.
FT   VARIANT     342    342       C -> W (in CS).
FT                                /FTId=VAR_017271.
FT   VARIANT     342    342       C -> Y (in CS and PS).
FT                                /FTId=VAR_004139.
FT   VARIANT     344    344       A -> G (in CS and JWS).
FT                                /FTId=VAR_004140.
FT   VARIANT     344    344       A -> P (in CS and PS).
FT                                /FTId=VAR_004141.
FT   VARIANT     347    347       S -> C (in CS).
FT                                /FTId=VAR_004142.
FT   VARIANT     351    351       S -> C (in CS, PS and ABS).
FT                                /FTId=VAR_004143.
FT   VARIANT     354    354       S -> C (in CS).
FT                                /FTId=VAR_004144.
FT   VARIANT     354    354       S -> Y (in CS).
FT                                /FTId=VAR_017272.
FT   VARIANT     356    358       Missing (in CS).
FT                                /FTId=VAR_004145.
FT   VARIANT     359    359       V -> F (in CS and PS).
FT                                /FTId=VAR_004146.
FT   VARIANT     362    362       A -> S (in CS).
FT                                /FTId=VAR_017273.
FT   VARIANT     372    372       S -> C (in Beare-Stevenson cutis gyrata
FT                                syndrome).
FT                                /FTId=VAR_017274.
FT   VARIANT     375    375       Y -> C (in PS and Beare-Stevenson cutis
FT                                gyrata syndrome).
FT                                /FTId=VAR_017275.
FT   VARIANT     384    384       G -> R (in CS).
FT                                /FTId=VAR_004147.
FT   VARIANT     526    526       K -> E (in FSPC).
FT                                /FTId=VAR_023788.
FT   VARIANT     549    549       N -> H (in CS).
FT                                /FTId=VAR_017276.
FT   VARIANT     565    565       E -> G (in PS).
FT                                /FTId=VAR_017277.
FT   VARIANT     612    612       R -> T (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_046071.
FT   VARIANT     613    613       G -> R.
FT                                /FTId=VAR_015012.
FT   VARIANT     628    628       A -> T (in LADDS).
FT                                /FTId=VAR_029884.
FT   VARIANT     641    641       K -> R (in PS).
FT                                /FTId=VAR_017278.
FT   VARIANT     648    648       A -> T (in LADDS).
FT                                /FTId=VAR_029885.
FT   VARIANT     649    650       RD -> S (in LADDS).
FT                                /FTId=VAR_029886.
FT   VARIANT     659    659       K -> N (in craniosynostosis).
FT                                /FTId=VAR_017279.
FT   VARIANT     663    663       G -> E (in PS).
FT                                /FTId=VAR_017280.
FT   VARIANT     678    678       R -> G (in CS).
FT                                /FTId=VAR_017281.
FT   STRAND      153    157
FT   HELIX       160    162
FT   STRAND      166    170
FT   STRAND      175    178
FT   STRAND      181    185
FT   STRAND      188    193
FT   HELIX       200    202
FT   TURN        211    213
FT   STRAND      215    218
FT   HELIX       223    225
FT   STRAND      227    235
FT   STRAND      238    249
FT   STRAND      266    269
FT   STRAND      274    277
FT   STRAND      287    293
FT   STRAND      309    314
FT   HELIX       321    325
FT   STRAND      326    329
FT   STRAND      338    345
FT   STRAND      350    360
FT   TURN        472    474
FT   HELIX       478    480
FT   STRAND      481    489
FT   STRAND      491    501
FT   STRAND      511    518
FT   HELIX       525    541
FT   STRAND      550    554
FT   STRAND      556    559
FT   STRAND      561    565
FT   HELIX       572    578
FT   HELIX       600    619
FT   STRAND      632    634
FT   STRAND      640    642
FT   TURN        657    659
FT   HELIX       667    669
FT   HELIX       672    676
FT   HELIX       682    697
FT   HELIX       709    718
FT   HELIX       730    739
FT   HELIX       744    746
FT   HELIX       750    762
SQ   SEQUENCE   821 AA;  92025 MW;  6CD5001C960ED82F CRC64;
     MVSWGRFICL VVVTMATLSL ARPSFSLVED TTLEPEEPPT KYQISQPEVY VAAPGESLEV
     RCLLKDAAVI SWTKDGVHLG PNNRTVLIGE YLQIKGATPR DSGLYACTAS RTVDSETWYF
     MVNVTDAISS GDDEDDTDGA EDFVSENSNN KRAPYWTNTE KMEKRLHAVP AANTVKFRCP
     AGGNPMPTMR WLKNGKEFKQ EHRIGGYKVR NQHWSLIMES VVPSDKGNYT CVVENEYGSI
     NHTYHLDVVE RSPHRPILQA GLPANASTVV GGDVEFVCKV YSDAQPHIQW IKHVEKNGSK
     YGPDGLPYLK VLKAAGVNTT DKEIEVLYIR NVTFEDAGEY TCLAGNSIGI SFHSAWLTVL
     PAPGREKEIT ASPDYLEIAI YCIGVFLIAC MVVTVILCRM KNTTKKPDFS SQPAVHKLTK
     RIPLRRQVTV SAESSSSMNS NTPLVRITTR LSSTADTPML AGVSEYELPE DPKWEFPRDK
     LTLGKPLGEG CFGQVVMAEA VGIDKDKPKE AVTVAVKMLK DDATEKDLSD LVSEMEMMKM
     IGKHKNIINL LGACTQDGPL YVIVEYASKG NLREYLRARR PPGMEYSYDI NRVPEEQMTF
     KDLVSCTYQL ARGMEYLASQ KCIHRDLAAR NVLVTENNVM KIADFGLARD INNIDYYKKT
     TNGRLPVKWM APEALFDRVY THQSDVWSFG VLMWEIFTLG GSPYPGIPVE ELFKLLKEGH
     RMDKPANCTN ELYMMMRDCW HAVPSQRPTF KQLVEDLDRI LTLTTNEEYL DLSQPLEQYS
     PSYPDTRSSC SSGDDSVFSP DPMPYEPCLP QYPHINGSVK T
//
